Results for “biotech”

STAT Biotech Meghana Keshavan

STAT+: Lawmakers want U.S. biotech to outcompete China

Lawmakers leading the congressional BIOTech Caucus say Washington needs to act in the sector — and fast:

Read at STAT Biotech

STAT Biotech Adam Feuerstein

STAT+: In cancer drug development, the spotlight shifts onto Erasca’s KRAS-targeted treatment

Did the biotech company Erasca find a more potent, better-tolerated pan-RAS cancer drug than Revolution Medicines?

Read at STAT Biotech

Axios Adriel Bettelheim

New alarm over China controlling drug supply chains

China is intensifying efforts to control the entire drug supply chain, putting the U.S. at risk of being cut off from future lifesaving treatments, the National Security Commission on Emerging Biotechnology warns in a new analysis out Thursday. Why it matters: Western drug giants have invested huge sums in Chinese biotechs to boost their product pipelines. But sharing capital and expertise could give Beijing more control over critical pharmaceutical technologies. Concerns…

Read at Axios

Nature Biotechnology Han Huang

Programmable functional RNA design with a virtual scientist

Nature Biotechnology, Published online: 19 November 2026; doi:10.1038/s41587-026-03362-3 RhoAgent designs functional RNA molecules by constraining secondary structure, base interactions and functional motifs.

Read at Nature Biotechnology

STAT Biotech Elaine Chen and Adam Feuerstein

STAT+: FDA discloses reasons for rejecting Summit drug

The FDA published its complete response letter to Summit Therapeutics explaining why it rejected the biotech's closely watched lung cancer drug:

Read at STAT Biotech

South China Morning Post Xinmei Shen Geopolitics

China still has ‘catching up to do’ to become biotech powerhouse, JPMorgan says

A lag in foundational research and looming geopolitical risks will weigh on China’s bid to build a world-class biotechnology innovation ecosystem, even as the sector’s overseas momentum remains strong, according to JPMorgan. “In China, there is still some catching up to do in basic research, particularly in biological and pharmaceutical research,” said Yang Huang, head of China healthcare research at JPMorgan, during an interview on Wednesday. To meet the “ambitious goal”…

Read at South China Morning Post

South China Morning Post Zoe SL Chan Geopolitics

Yicura BioMed eyes IPO as CEO says Hong Kong biotech scene needs more patient capital

Hong Kong needs more “patient capital” and more talent capable of commercialising research and development to sustain the city’s biotechnology ecosystem, according to a senior executive at a local biotech start-up. Yicura BioMed, based in the Hong Kong Science Park, is heading towards an initial public offering (IPO) in the city as soon as practicable, CEO Xian Jin said in an interview. “Biotech start-up fundraising in Hong Kong is never an easy game to play,” Jin said…

Read at South China Morning Post

Green Queen (alternative protein) Anay Mridul

All G Cleared to Sell Recombinant Breast Milk Protein in US, Targets Adult Nutrition & Supplements

4 Mins ReadAustralian biotech startup All G has self-determined its precision-fermented human lactoferrin as GRAS in the US, the first in an expanding pipeline of breast milk proteins. All G has been cleared to sell its recombinant human lactoferrin protein in the US. The Sydney-based firm has secured self-affirmed Generally Recognized as Safe (GRAS) status for its

Read at Green Queen (alternative protein)

YourStory Startups

Karnataka aims to become a global hub for frontier tech; Fadnavis’ vision for a new Maharashtra

Karnataka aims to become a global hub for frontier technologies such as AI, deeptech, and biotech, said CM DK Shivakumar at Bengaluru Tech Summit. Meanwhile, Maharashtra CM Fadnavis has shared his roadmap for a trillion-dollar, drought-free, deeptech Maharashtra by 2035.

Read at YourStory

STAT Biotech Elaine Chen

STAT+: Flagship opens biotech-creation outpost in the U.K.

Flagship is putting up 100 million pounds to start “AI-native platform companies" focused on human and planetary health in the U.K.:

Read at STAT Biotech

BioPharma Dive Kristin Jensen

AI drugmaker Isomorphic restocks with $5B fundraise

Even as the larger AI industry faces turmoil, investors have given Isomorphic the two largest cash infusions in the biotech sector this year.

Read at BioPharma Dive

Crunchbase News Judy Rider Startups

PwC’s IPO Lead On A Selective Market, AI Valuations And The Outlook For 2027

In this Q&A, Mike Bellin, a partner and U.S. IPO services leader at PricewaterhouseCoopers, discussed the slowdown in IPO momentum, how public investors are evaluating AI companies, biotech’s resurgence and why SPACs are attracting renewed interest. He also outlined what could set the stage for a stronger start to 2027.

Read at Crunchbase News

YourStory Startups

Karnataka aims to become global hub for frontier technologies: DK Shivakumar

Karnataka Chief Minister DK Shivakumar said the strong technology ecosystem in the State gives it the advantage to lead in areas such as AI, biotech, semiconductor and robotics.

Read at YourStory

Nature Biotechnology Yongjian Chen

Author Correction: The global patent landscape of bispecific antibodies: technological innovations and therapeutic applications

Nature Biotechnology, Published online: 17 November 2026; doi:10.1038/s41587-026-03405-9 Author Correction: The global patent landscape of bispecific antibodies: technological innovations and therapeutic applications

Read at Nature Biotechnology

NASA Science Space

Biotechnology, Spacesuit Work, and Dragon Packing Start Week Aboard Station

Biotechnology research including growing human lung cells and managing blood flow in space awaited the Expedition 75 crew on Monday. Spacesuit checks, cargo packing, and Earth observations rounded out the busy schedule aboard the International Space Station at the beginning of the week.

Read at NASA Science

STAT Biotech Meghana Keshavan

STAT+: Biotech’s rebound isn’t lifting all boats equally

Biotech is having a good year, though you wouldn't necessarily know it from how investors are treating positive clinical data.

Read at STAT Biotech

Analytics India Magazine Supreeth Koundinya SI

Karnataka Bets on Physical AI, Deeptech at Bengaluru Tech Summit 2026

Bengaluru Tech Summit 2026 aims to extend AI adoption beyond enterprise software into agriculture, biotechnology, gaming, industrial systems, and e-governance.

Read at Analytics India Magazine

STAT Biotech Damian Garde

BeOne, Hengrui top list of China’s most powerful drugmakers

A new STAT-WireScreen index ranks China's most valuable publicly traded biotech companies. See which one topped the list.

Read at STAT Biotech

BioPharma Dive Gwendolyn Wu

One of Europe’s leading VCs banks a €725M ‘crossover’ fund

Sofinnova Partners, which has backed the likes of successful drugmakers such as Abivax, Argenx and Verona Pharma, will use the cash to support a new group of later-stage biotechs.

Read at BioPharma Dive

Nature Biotechnology Lingjuan Hong

A CD7-targeted AAV variant enables efficient T and NK cell engineering in vivo

Nature Biotechnology, Published online: 16 November 2026; doi:10.1038/s41587-026-03344-5 Adeno-associated virus vectors targeted to CD7 enable T and NK cell engineering in vivo.

Read at Nature Biotechnology

STAT Biotech Adam Feuerstein

STAT+: FDA rejects lung cancer treatment ivonescimab from Summit Therapeutics

The FDA has rejected ivonescimab, a treatment for a type of lung cancer developed by U.S. biotech Summit Therapeutics and the Chinese drugmaker Akeso.

Read at STAT Biotech

Green Queen (alternative protein) Anay Mridul

India’s Symbiotec Pharmalabs to Produce Precision-Fermented Protein for EU Partner in 10-Year Deal

4 Mins ReadIndian biotech firm Symbiotec Pharmalabs has signed a 10-year deal to serve as a contract manufacturer for a European company’s precision-fermented protein. Shoring up India’s biomanufacturing prowess, Symbiotec Pharmalabs has expanded its contract manufacturing services for a European innovator in alternative proteins. The biotech firm has signed a 10-year take-or-pay agreement with an unnamed European

Read at Green Queen (alternative protein)

Asia Times Damien Ng Geopolitics

China’s demographic challenge becoming its biotech advantage

Is biotechnology becoming the next space race? The Biotechnology Innovation Organization (BIO) appears to think so. This month, it urged Washington to adopt a comprehensive national biotechnology strategy, warning that China is rapidly gaining ground in an industry now viewed as critical to economic competitiveness and national security. The United States and China have spent

Read at Asia Times

BioPharma Dive Gwendolyn Wu

Windward prices $175M IPO to advance China-licensed lung drugs

The Swiss biotech has two prospects it sees as having the potential to outcompete AstraZeneca and Amgen's blockbuster asthma treatment Tezspire.

Read at BioPharma Dive

Nature Biotechnology Thomas Burger

A unified and practical taxonomy for false discovery rate control in omics research

Nature Biotechnology, Published online: 13 November 2026; doi:10.1038/s41587-026-03379-8 False discovery rate (FDR) control is central to omics research, yet the diverse procedures used rely on different assumptions. This Comment proposes a 2 × 2 matrix that helps sequencing-based and mass-spectrometry-based omics researchers choose the appropriate family of FDR procedures, or alternative methods that may be more rigorous, depending on data and study design.

Read at Nature Biotechnology

Green Queen (alternative protein) Anay Mridul

Oobli: US Sweet Protein Startup Acquired by Precision Fermentation Player Amyris

5 Mins ReadCalifornian sweet protein pioneer Oobli has agreed to an acquisition by Amyris, a biotech firm specialising in precision fermentation, to expand the scale of its sugar reduction portfolio. US biomanufacturing company Amyris has announced it will acquire Oobli, a California-based producer of precision-fermented sweet proteins. The transaction amount is undisclosed. It combines the former’s strain

Read at Green Queen (alternative protein)

STAT Biotech Adam Feuerstein

STAT+: Alnylam, once in the hunt to be a $100 billion biotech, needs to solve its heart drug problem

Alnylam is heavily dependent on its heart drug Amvuttra for growth — and sales have been slowing.

Read at STAT Biotech

Nature Biotechnology Sojin Bing

A comprehensive analysis of CBER experience with AAV gene therapy IND submissions

Nature Biotechnology, Published online: 12 November 2026; doi:10.1038/s41587-026-03378-9 An analysis of Investigational New Drug (IND) submissions to the US Food and Drug Administration (FDA) from 1995 to 2025 reveals a rapid growth in adeno-associated virus (AAV) development over three decades and highlights common reasons for regulatory holds that should be considered for successful product development.

Read at Nature Biotechnology

Tech.eu Cate Lawrence Startups

Inside Biscay's startup ecosystem: Industrial strengths, public investment, and deeptech ambition

Biscay (Bizkaia), in Spain’s Basque Country, is building on its industrial heritage to develop a startup ecosystem spanning biotechnology, advanced manufacturing, energy and emerging technologies. Wit...

Read at Tech.eu

BioPharma Dive BioPharma Dive staff

AstraZeneca buys vaccine startup; FDA issues GLP-1 safety warning

The deal gives AstraZeneca a simpler way to make conjugate vaccines. Elsewhere, a psychedelic depression drug was submitted to the FDA and an autoimmune disease-focused biotech’s shares collapsed.

Read at BioPharma Dive

Older stories